Loading
IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.84, animal model 0.52, genetic association 0.00, clinical 0.96). In OnCo, 1 product record names it (Bempegaldesleukin).
In plain words · IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.
IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.
No product in this corpus aims at IL2RB yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Lineage antigen shared with normal NK-cells and T-cells and bone marrow cells and lymphoid tissue cells: HPA finds the gene tissue enhanced in bone marrow, lymphoid tissue, and the 1 medicine aimed at it (Bempegaldesleukin) act on the wild-type protein, so the normal lineage is hit too. HPA IL2RB: RNA tissue enhanced (bone marrow 33 nTPM, lymphoid tissue 46 nTPM); blood lineage group enriched (NK-cells 184 nTPM, T-cells 50 nTPM); no normal tissue stained high. Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Leukaemia, Renal cell carcinoma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (primary cutaneous T-cell non-Hodgkin lymphoma, renal cell carcinoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas IL2RB tissue; Human Protein Atlas IL2RB pathology; Open Targets ENSG00000100385 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Hatakeyama et al, Science, 1989, "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's". Source.
Sources: HGNC HGNC:6009 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P14784 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000100385 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: renal cell carcinoma 0.52, melanoma 0.55, non-Hodgkin lymphoma 0.51, skin cancer 0.56, leukaemia 0.53, primary cutaneous T-cell non-Hodgkin lymphoma 0.55 (GraphQL API, CC0))
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Location: Cell membrane (UniProt). Locus 22q12.3 (HGNC).
RNA: tissue enhanced (bone marrow 33 nTPM, lymphoid tissue 46 nTPM), detected in many normal tissues. Blood: group enriched (NK-cells 184 nTPM, T-cells 50 nTPM).
No normal tissue stained high; medium in Bone marrow, Endometrium, Lymph node, Spleen, Tonsil.
No cancer sample stained medium or high.
HPA IL2RB tissue · HPA IL2RB pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IL2RB" OR ABSTRACT:"IL2RB" OR TITLE:"interleukin 2 receptor subunit beta" OR ABSTRACT:"interleukin 2 receptor subunit beta" OR TITLE:"Interleukin-2 receptor subunit beta" OR ABSTRACT:"Interleukin-2 receptor subunit beta" OR TITLE:"CD122" OR ABSTRACT:"CD122" OR TITLE:"IL15RB" OR ABSTRACT:"IL15RB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL2RB, not a curated reading list.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Leukaemia (all types), Renal cell carcinoma, Skin cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Melanoma.
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Skin cancer (all types), Melanoma, Open Targets Platform.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Melanoma, Open Targets Platform.
Shares Leukaemia (all types), Renal cell carcinoma, Skin cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Melanoma.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Melanoma, Open Targets Platform.